The CrickConnect team are delighted to be able to invite community members to join us for the institute's regular Crick Lecture.

Crick Lectures provide a broad insight into biomedical research from leading scientists. Not to be missed, the one-hour lectures are the event of the week for the Crick community to come together. 

This installment will be delivered by Crick Senior Group Leader and CRUK Chief Clinician Charles Swanton.

Crick Lectures take place weekly (usually on Thursday at 16:00). They are given by leading scientists and aim to be accessible to scientists across different disciplines, while also offering something for the specialist.

Due to the pioneering and sensitive nature of some of the research discussed in these lectures, only Crick Lectures from selected Crick group leaders will be shared, and we ask all attendees to respect the private nature of these talks by refraining from making any type of recording, sharing access details or in any other way compromising the research that is discussed.

Speaker Profile

Professor Charles Swanton FRCP BSc PhD is a clinician scientist, focusing his work on understanding the challenges inherent in the management of metastatic cancer and their drug resistant and incurable nature. 

Charles completed his PhD in 1998 at the Imperial Cancer Research Fund Laboratories on the UCL MBPhD programme before completing his medical oncology and Cancer Research UK (CRUK) funded postdoctoral clinician scientist training in 2008.

He was appointed CRUK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the London Research Institute (now part of the Francis Crick Institute) and consultant medical oncologist at the Royal Marsden Hospital in 2008. Charles was appointed Fellow of the Royal College of Physicians, Chair in Personalised Cancer Medicine at the UCL Cancer Institute and Consultant Thoracic Medical Oncologist at UCL Hospitals in 2011.

Charles is the Chief Investigator of the CRUK TRACERx clinical study to decipher lung cancer evolution and is co-director of the CRUK Lung Cancer Centre of Excellence.